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BACKGROUND: Primary percutaneous coronary intervention is frequently successful 
at restoring coronary artery blood flow in patients with acute ST-segment–elevation 
myocardial infarction; however, failed myocardial reperfusion commonly passes 
undetected in up to half of these patients. The index of microvascular resistance 
(IMR) is a novel invasive measure of coronary microvascular function. We aimed 
to investigate the pathological and prognostic significance of an IMR>40, alone or 
in combination with a coronary flow reserve (CFR≤2.0), in the culprit artery after 
emergency percutaneous coronary intervention for acute ST-segment–elevation 
myocardial infarction.
METHODS: Patients with acute ST-segment–elevation myocardial infarction were 
prospectively enrolled during emergency percutaneous coronary intervention and 
categorized according to IMR (≤40 or >40) and CFR (≤2.0 or >2.0). Cardiac magnetic 
resonance imaging was acquired 2 days and 6 months after myocardial infarction. 
All-cause death or first heart failure hospitalization was a prespecified outcome (median 
follow-up, 845 days).
RESULTS: IMR and CFR were measured in the culprit artery at the end of percutaneous 
coronary intervention in 283 patients with ST-segment–elevation myocardial infarction 
(mean±SD age, 60±12 years; 73% male). The median IMR and CFR were 25 
(interquartile range, 15–48) and 1.6 (interquartile range, 1.1–2.1), respectively.  
An IMR>40 was a multivariable associate of myocardial hemorrhage (odds ratio, 2.10; 
95% confidence interval, 1.03–4.27; P=0.042). An IMR>40 was closely associated 
with microvascular obstruction. Symptom-to-reperfusion time, TIMI (Thrombolysis 
in Myocardial Infarction) blush grade, and no (≤30%) ST-segment resolution were 
not associated with these pathologies. An IMR>40 was a multivariable associate of 
the changes in left ventricular ejection fraction (coefficient, −2.12; 95% confidence 
interval, −4.02 to −0.23; P=0.028) and left ventricular end-diastolic volume 
(coefficient, 7.85; 95% confidence interval, 0.41–15.29; P=0.039) at 6 months 
independently of infarct size. An IMR>40 (odds ratio, 4.36; 95% confidence interval, 
2.10–9.06; P<0.001) was a multivariable associate of all-cause death or heart failure. 
Compared with an IMR>40, the combination of IMR>40 and CFR≤2.0 did not have 
incremental prognostic value.
CONCLUSIONS: An IMR>40 is a multivariable associate of left ventricular and clinical 
outcomes after ST-segment–elevation myocardial infarction independently of the 
infarction size. Compared with standard clinical measures of the efficacy of myocardial 
reperfusion, including the ischemic time, ST-segment elevation, angiographic blush 
grade, and CFR, IMR has superior clinical value for risk stratification and may be 
considered a reference test for failed myocardial reperfusion.
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Despite the success of emergency percutaneous coro-nary intervention (PCI) in restoring coronary blood flow in patients with acute ST-segment–elevation 
myocardial infarction (STEMI), a failure of myocardial reper-
fusion, which manifests initially as microvascular obstruc-
tion and then subsequently as myocardial hemorrhage, 
affects approximately half of patients with acute STEMI.1,2 
Microvascular pathology (specifically, microvascular ob-
struction and myocardial hemorrhage) revealed by cardiac 
magnetic resonance (CMR) is prognostically important3–5; 
however, CMR is neither feasible acutely nor routinely rec-
ommended. Established tests for failed reperfusion such 
as the surface ECG, a test focused on ST-segment resolu-
tion and performed 60 to 90 minutes after reperfusion,6 
and the angiographic tissue myocardial perfusion grade7,8 
lack sensitivity and reproducibility in routine practice.9 
Failed myocardial reperfusion passes undetected in up to 
half of patients after acute STEMI.3,4
Invasive assessment of microcirculatory function at the 
end of emergency PCI before the patient is transferred to 
the ward presents an opportunity to identify STEMI patients 
with failed myocardial reperfusion with greater accuracy 
than the angiogram or the ECG. The index of microvascular 
resistance (IMR) is independently associated with left ven-
tricular (LV) function10 and infarct pathology,11,12 and in a 
recent study, an IMR>40 was a multivariable associate of 
mortality after STEMI.13 Coronary flow reserve (CFR) reflects 
epicardial and microvascular vasodilator capacity.14 CFR is 
associated with composite cardiovascular outcomes, in-
cluding revascularization, in patients with stable coronary 
disease15 and after acute STEMI.16 We have recently shown 
that IMR is more closely associated with severe microvas-
cular pathology, LV remodeling, and health outcome than 
either the angiogram or CFR,17 but whether the combina-
tion of IMR and CFR adds prognostic value is uncertain.
Different IMR cutoffs have been proposed,10–13 but 
only an IMR>40 is associated with mortality.13 The com-
bination of an increased IMR and reduced CFR has been 
associated with enhanced detection of microvascular 
obstruction18 and viability and prognosis.16 However, in 
that study, only 10 major adverse cardiac and cerebro-
vascular events occurred, of which 5 were revascular-
izations. Changes in IMR and CFR within 24 hours af-
ter reperfusion have been associated with LV ejection 
fraction (LVEF).19,20 However, prior studies are limited by 
sample size (n=27–45 subjects),10,20–22 short follow-up 
(3–6 months),10,18,20–22 lack of association with sponta-
neous hard outcomes,16 and differences in cutoffs,12,23 
supporting the case for definitive research.
Building on prior literature, we hypothesized that 
in patients with an acute STEMI, an IMR>40 would be 
more closely associated with infarct pathology and clini-
cal outcomes than established angiographic and ECG 
measures of myocardial reperfusion and that, compared 
with IMR alone, the combination of an IMR>40 and a 
CFR≤2.0 might be more closely associated with infarct 
pathologies and prognosis. We measured IMR and CFR 
simultaneously in the culprit coronary artery immediately 
after emergency PCI in a large, unselected population of 
patients with acute STEMI.
MethODs
study Population and steMi Management
We performed a prospective cohort study in a regional cardiac 
center between July 14, 2011, and November 22, 2012. Two 
hundred eighty-eight patients with STEMI were enrolled by 13 
cardiologists. The patients provided written informed consent 
to undergo a diagnostic guidewire-based assessment after 
reperfusion and then CMR 2 days and 6 months later, as well 
as follow-up for health outcomes in the longer term.
Patients were eligible if they had an indication for primary PCI 
or thrombolysis for acute STEMI.24,25 Exclusion criteria included 
standard contraindications to CMR, for example, a pacemaker. 
The study was approved by the National Research Ethics Service 
(reference 10-S0703-28). Acute STEMI management (Methods 
in the online-only Data Supplement) followed contemporary 
guidelines.24,25 The ClinicalTrials.gov identifier is NCT02072850.
clinical Perspective
What is new?
•	The index of microvascular resistance (IMR) and 
coronary flow reserve were routinely measured in 
the culprit coronary artery of a reasonably large 
cohort of patients with acute ST-segment–elevation 
myocardial infarction treated by emergency percuta-
neous coronary intervention.
•	Compared with ischemic time and angiographic and 
electrocardiographic measures of reperfusion, an 
IMR>40 was more consistently and strongly asso-
ciated with microvascular pathology, changes in 
left ventricular function and volumes, and all-cause 
death and heart failure in the longer term.
•	Compared with an IMR>40, the combination of 
IMR>40 and coronary flow reserve ≤2.0 did not 
have additional prognostic value.
What are the clinical implications?
•	Despite the routine success of primary percutane-
ous coronary intervention, failed myocardial reperfu-
sion is common and usually passes undetected.
•	 IMR has emerging clinical utility as a routine test for 
the efficacy of myocardial reperfusion in invasively 
managed patients with acute ST-segment–elevation 
myocardial infarction.
•	An IMR>40 represents a prognostically validated ref-
erence test for failed myocardial reperfusion at the 
end of primary percutaneous coronary intervention.
•	Our results confirm previous investigations and sup-
port further research into IMR-based therapeutic 
strategies in patients with acute ST-segment–eleva-
tion myocardial infarction.
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Measurement of cFr and iMr in the culprit 
coronary artery at the end of Pci
We adopted a thermodilution technique rather than Doppler 
because we wished to implement a method that is most 
transferable to routine clinical practice. In our experience, the 
Doppler measurements can be more time-consuming, require 
considerable experience, and may be less reproducible,14 and 
the guidewire is typically more expensive.
A coronary pressure- and temperature-sensitive guide 
wire (St. Jude Medical, St. Paul, MN) was used to measure 
IMR and CFR in the culprit coronary artery at the end of pri-
mary or rescue PCI. The guidewire was calibrated outside 
the body, equalized with aortic pressure at the ostium of 
the guide catheter. and then advanced to the distal third 
of the culprit artery. This thermodilution method is based 
on the following basic relationship: flow=volume/mean tran-
sit time. CFR is defined as the ratio of peak hyperemic to 
resting flow (CFR=flow at hyperemia/flow at rest). Flow is 
the ratio of the volume (V) divided by the mean transit time 
(Tmn). Thus, CFR can be expressed as follows: CFR=(V/
Tmn) at hyperemia/(V/Tmn) at rest. Assuming that the epi-
cardial volume remains unchanged, CFR can be calculated 
as follows: CFR=Tmn at rest/Tmn at hyperemia. CFR and 
IMR are distinct physiological parameters. CFR reflects epi-
cardial and microcirculatory function. In contrast, IMR is a 
direct invasive measure of microvascular resistance. IMR is 
defined as the distal coronary pressure multiplied by the 
mean transit time of a 3-mL bolus of saline at room tempera-
ture during maximal coronary hyperemia measured simulta-
neously (mm Hg·s or units).10–12
Hyperemia was induced by 140 μg·kg−1·min−1 of intrave-
nous adenosine preceded by a 2-mL intracoronary bolus of 
200 µg nitrate. The mean aortic and distal coronary pressures 
were recorded during maximal hyperemia. We have previously 
found IMR to be highly repeatable when assessed by duplicate 
measurements 5 minutes apart in 12 consecutive patients with 
STEMI at the end of PCI.12
On the basis of prior literature, we prespecified and exam-
ined an IMR>40 and the following classifications: (1) IMR≤40 
and CFR>2.0, (2) IMR>40 and CFR>2.0, (3) IMR≤40 and 
CFR≤2.0, and (4) IMR>40 and CFR≤2.0.
cMr imaging
We used CMR to provide reference data on LV function, 
pathology, and surrogate outcomes independently of the 
invasive tests (Figure 1). CMR was performed on a Siemens 
MAGNETOM Avanto (Erlangen, Germany) 1.5-T scanner with 
a 12-element phased-array cardiac surface coil.26 The imag-
ing protocol5,27 (Methods in the online-only Data Supplement) 
included cine magnetic resonance imaging with steady-state 
free precession, T2 mapping,28,29 T2* mapping, and delayed-
enhancement phase-sensitive inversion-recovery pulse 
sequences.30 The scan acquisitions were spatially coregis-
tered and included different slice orientations to enhance 
diagnostic confidence.
imaging analyses
The CMR analyses are described in detail in Methods in the 
online-only Data Supplement.
infarct Definition and size
The presence of acute infarction was established on the 
basis of abnormalities in cine wall motion, rest first-pass 
myocardial perfusion, and delayed-enhancement imaging in 
2 imaging planes. The myocardial mass of late gadolinium 
(grams) was quantified with computer-assisted planimetry, 
and the territory of infarction was delineated with the use 
of a signal intensity threshold of >5 SD above a remote 
reference region and expressed as a percentage of total 
LV mass.31
Microvascular Obstruction
Microvascular obstruction was defined as a dark zone on early 
gadolinium enhancement imaging 1, 3, 5, and 7 minutes after 
contrast injection that remained present within an area of late 
gadolinium enhancement at 15 minutes.
Myocardial edema
The extent of myocardial edema was defined as LV 
myocardium with pixel values (T2) >2 SD from remote 
myocardium.28,29,32–35
Myocardial salvage
Myocardial salvage was calculated by subtracting the percent 
infarct size from percent area at risk, as reflected by the extent 
of edema.12,32,35 The myocardial salvage index was calculated 
by dividing the myocardial salvage area by the initial area at 
risk.
lV remodeling
An increase in LV volume at 6 months from baseline was taken 
to reflect LV remodeling.27,35,36 Adverse remodeling was defined 
as an increase in LV end-diastolic volume (LVEDV) ≥20% at 6 
months from baseline.27
Myocardial hemorrhage
On the T2* CMR maps, a region of reduced signal intensity 
within the infarcted area with a T2* value of <20 millisec-
onds4,37–40 was considered to confirm the presence of myocar-
dial hemorrhage.
electrocardiography
A 12-lead ECG was obtained before coronary reperfusion and 
60 minutes afterward. The extent of ST-segment resolution on 
the ECG assessed 60 minutes after reperfusion compared with 
the baseline ECG before reperfusion41 was expressed as com-
plete (≥70%), incomplete (30%–<70%), or none (≤30%).
coronary angiogram acquisition and analyses
Coronary angiograms were acquired during usual care with 
cardiac catheter laboratory x-ray (Innova, GE Healthcare) 
and information technology equipment (Centricity, GE 
Healthcare). The angiograms were analyzed by trained 
observers (J.C., V.T.Y.M) who were blinded to all other 
clinical and MRI data. The TIMI (Thrombolysis in Myocardial 
Infarction) coronary flow grade42 and frame count43 were 
assessed at initial angiography and at the end of the pro-
cedure. TIMI myocardial perfusion grade44 was assessed at 
the end of the procedure (Methods in the online-only Data 
Supplement).
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laboratory analyses
The acquisition of blood samples for biochemical and hemato-
logic analyses is described in Methods in the online-only Data 
Supplement.
Prespecified health Outcomes
We prespecified adverse health outcomes that are patho-
physiologically linked with STEMI.45,46 The primary composite 
outcome was all-cause death or first heart failure event after 
Figure 1. Four patients with acute st-segment–elevation myocardial infarction treated by primary percutane-
ous coronary intervention (Pci).  
Each patient had index of microvascular resistance (IMR) and coronary flow reserve (CFR) measured in the culprit coro-
nary artery at the end of the procedure. The patients reflect the following categories: IMR≤40 and CFR>2.0; IMR≤40 and 
CFR≤2.0; IMR>40 and CFR>2.0; and IMR>40 and CFR≤2.0. The patients were treated with similar antithrombotic therapy, 
including aspirin, clopidogrel, heparin, and intravenous glycoprotein IIb/IIIa inhibitor therapy with tirofiban. Each patient had 
normal TIMI (Thrombolysis in Myocardial Infarction) grade 3 flow at the end of PCI. Cardiac magnetic resonance imaging 
(MRI) was performed for each patient 2 days later. A, A patient with a normal IMR and a normal CFR. Invasive assessment 
of microvascular function in the culprit coronary artery at the end of primary PCI indicated that microcirculatory function 
was preserved. Cardiac magnetic resonance (CMR) subsequently revealed nontransmural late gadolinium enhancement 
consistent with salvaged myocardium. There was no evidence of myocardial hemorrhage (middle right) or microvascu-
lar obstruction (right). B, A patient with a normal IMR and a low CFR. Late gadolinium contrast CMR revealed transmural 
inferior myocardial infarction with a small central zone of hypointense microvascular obstruction (arrow, right). T2*-CMR 
excluded myocardial hemorrhage within the infarct core (middle right). C, A patient with a high IMR and a normal CFR. Late 
gadolinium contrast-enhanced CMR revealed transmural anteroseptal myocardial infarction complicated by microvascular 
obstruction (arrow, right). T2*-CMR (arrow, middle right) revealed myocardial hemorrhage within the infarct core, and 
microvascular obstruction spatially corresponded with the myocardial hemorrhage. D, A patient with a high IMR and a low 
CFR. Invasive guidewire-based physiological testing at the end of primary PCI revealed severe microvascular dysfunction. 
Transmural myocardial infarction and microvascular obstruction are present, in association with abundant myocardial hemor-
rhage (arrow, middle right).
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the initial hospitalization (Methods in the online-only Data 
Supplement).
statistical analyses
The sample size calculation and statistical methods are 
described in the Methods in the online-only Data Supplement. 
Random-effects models were used to compute interrater and 
intrarater reliability measures (intraclass correlation coef-
ficient) for the reliability of angiographic measures of myo-
cardial reperfusion measured independently by 2 observers 
in 20 randomly selected patients from the cohort (Results in 
the online-only Data Supplement). All P values are 2-sided, 
and value of P >0.05 indicates the absence of a statistically 
significant effect. Statistical analyses were performed with R 
version 2.15.1, SAS version 9.3, or higher versions of these 
programs.
resUlts
Patient characteristics and iMr and cFr 
Measured acutely in the culprit coronary artery 
after reperfusion
A total of 283 patients with STEMI had IMR and CFR 
measured in the culprit coronary artery at the end of 
emergency PCI (Table 1 and Figure 2). The median IMR 
and CFR were 25 (interquartile range, 15–48) and 1.6 
(interquartile range, 1.1–2.1), respectively. A CFR≤2.0, 
an IMR>40, or both occurred in 210 (74%), 79 (28%) 
(Table 1), and 65 (23%) patients, respectively (Table I in 
the online-only Data Supplement).
cMr Findings
CMR imaging occurred 2.1±1.8 days later, and 264 pa-
tients (93%) had follow-up CMR at 6 months (Table 2 and 
Figure 2). Case examples are shown in Figure 1. Myo-
cardial hemorrhage and microvascular obstruction oc-
curred in 89 (42%) and 114 (54%) patients, respectively. 
An IMR>40 (Table 2) and the combination of an IMR>40 
and a CFR≤2.0 (Table II in the online-only Data Supple-
ment) were associated with LVEF and infarct pathology 2 
days after MI and LVEF at 6 months.
Multivariable associations for an iMr>40 With 
Microvascular infarct Pathology revealed by 
cMr
Myocardial Hemorrhage
In a binary logistic regression model with baseline char-
acteristics, an IMR>40 was a multivariable associate 
of myocardial hemorrhage (odds ratio [OR], 2.86; 95% 
confidence interval [CI], 1.52–5.39; P=0.001; Table 3), 
whereas symptom-to-reperfusion time, TIMI blush grade, 
and no ST-segment resolution were not.
Microvascular Obstruction
An IMR>40 was a multivariable associate of microvascu-
lar obstruction (OR, 2.82; 95% CI, 1.62–4.93; P<0.001; 
Table III in the online-only Data Supplement). Symptom-to-
reperfusion time, TIMI blush grade, and no ST-segment 
resolution were not multivariable associates of microvas-
cular obstruction.
Microvascular Infarct Pathologies and Invasive 
Microvascular Parameters in Combination
The combination of IMR>40 and CFR≤2.0 was a multi-
variable associate with microvascular obstruction (OR, 
2.28; 95% CI, 1.16–4.46; P=0.016) but not with myo-
cardial hemorrhage (P=0.104).
Compared with IMR>40 and CFR≤2.0 (reference 
group), the group with the combination of IMR≤40 and 
CFR≤2.0 was associated with a reduced odds of micro-
vascular obstruction (OR, 0.19; 95% CI, 0.05–0.76; 
P=0.019) and myocardial hemorrhage (OR, 0.17; 95% 
CI, 0.03–0.92; P=0.040).
Microvascular Dysfunction and subsequent lV 
Outcomes
Changes in LVEDV
An IMR>40 was a univariable (regression coefficient, 
11.43; 95% CI, 4.07–18.79; P=0.002) and a multivari-
able (regression coefficient, 7.85; 95% CI, 0.41–15.29; 
P=0.039) associate of the changes in LVEDV, including 
after adjustment for infarct size (n=264; Table 4).
Changes in LVEF
An IMR>40 was a univariable (regression coefficient, 
−2.89; 95% CI, −4.89 to −0.91; P=0.004, with adjust-
ment for baseline LVEF) and a multivariable (regression 
coefficient, −2.12; 95% CI, −4.02 to −0.23; P=0.028) 
associate of the changes in LVEF at 6 months from 
baseline, including after adjustment for infarct size, as 
reflected by troponin or contrast-enhanced MRI (n=264; 
Table IV in the online-only Data Supplement).
LV Outcomes and the Combination of IMR>40 and CFR≤2.0
Results for the multivariable models for IMR>40 com-
bined with CFR≤2.0 were not improved compared with 
the model with IMR>40 (Tables IV and V in the online-only 
Data Supplement, footnote).
Microvascular Dysfunction and longer-term 
health Outcomes
All of the patients (n=283) had completed long-term 
follow-up data. The median duration of follow-up was of 
845 days (range of postdischarge censor duration, 598–
1098 days). Thirty patients (11%) died or experienced a 
first heart failure event during the index hospitalization or 
after discharge. These events included 5 cardiovascular 
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table 1. clinical and angiographic characteristics of 283 Patients With steMi categorized according to an 
iMr≤40 or >40 Measured in the culprit coronary artery at the end of Pci
characteristics* all Patients (n=283) iMr≤40 (n=204, 72%) iMr>40 (n=79, 28%) P Value
Age, y 60 (12) 59 (11) 62 (12) 0.093 (t)
Male sex, n (%) 206 (73) 147 (72) 59 (75) 0.766
BMI, kg/m2 29 (5) 29 (5) 28 (5) 0.009 (t)
Medical history, n (%)
  Hypertension 91 (32) 60 (29) 31 (39) 0.120
  Current smoking 175 (62) 130 (64) 45 (57) 0.340
  Hypercholesterolemia 78 (28) 55 (27) 23 (29) 0.767
  Diabetes mellitus† 30 (11) 21 (10) 9 (11) 0.830
  Previous angina 32 (11) 22 (11) 10 (13) 0.678
  Previous MI 20 (7) 15 (7) 5 (6) 1.000
  Previous PCI 14 (5) 9 (4) 5 (6) 0.544
Presenting characteristics
  Heart rate, bpm 78 (17) 78 (17) 78 (16) 0.800 (t)
  Systolic blood pressure, mm Hg 136 (24) 135 (25) 136 (24) 0.797 (t)
  Diastolic blood pressure, mm Hg 79 (14) 79 (14) 80 (13) 0.358 (t)
  Time from symptom onset to reperfusion, min 174 (120–316) 171 (119–300) 179 (129–364) 0.208 (MW)
  Ventricular fibrillation,‡ n (%) 19 (7) 11 (5) 8 (10) 0.185
  Heart failure, Killip class at presentation, n (%) 201 (71) 158 (80) 43 (54)  
   I     
   II 62 (22%) 40 (20) 22 (28) <0.001
   III/IV 20 (7) 6 (3) 14 (18)  
  ECG     
  ST-segment elevation resolution after PCI, n (%)
   Complete, ≥70% 128 (45) 23 (11) 17 (22)  
   Incomplete, 30%–<70% 114 (40) 79 (39) 35 (44) 0.022
   None, ≤30% 40 (14) 23 (11) 27 (34)  
Reperfusion strategy, n (%)
  Primary PCI 262 (93) 189 (93) 73 (92)  
  Rescue PCI (failed thrombolysis) 14 (5) 10 (5) 4 (5) 1.000
  Successful thrombolysis 7 (2) 5 (3) 2 (3)  
Coronary angiography
  No. of diseased arteries,§ n (%)
   1 158 (56) 112 (55) 46 (58)  
   2 83 (29) 61 (30) 22 (28) 0.973
   3 37 (13) 27 (13) 10 (13)  
  Culprit artery, n (%)
   LM 5 (2) 4 (2) 1 (1)  
   LAD 107 (38) 72 (35) 35 (44)  
   LCx 51 (18) 39 (19) 12 (15) 0.371
   RCA 125 (44) 93 (46) 32 (40)  
(Continued )
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deaths, 3 noncardiovascular deaths, and 22 episodes 
of heart failure (Killip class 3 or 4 heart failure [n=20] or 
defibrillator implantation [n=2]). Ten patients (3.5%) died 
or experienced a first heart failure hospitalization after 
discharge (Table V in the online-only Data Supplement).
IMR was a univariable associate of all-cause death or 
heart failure, whereas CFR was not (Table 5). Because of 
the number of events observed, 2 multivariable models 
were considered: 1 model with hypertension and smok-
ing as covariates and 1 model with ST-segment resolu-
tion (none) and TIMI frame count (Table 5). In the model 
with smoking and hypertension, an IMR>40 (OR, 4.70; 
95% CI, 2.10–10.53; P<0.001) was a multivariable as-
sociate of all-cause death or heart failure. In the model 
  TIMI coronary flow grade before PCI, n (%)
   0/1 204 (72) 141 (69) 63 (80)  
   2/3 79 (28) 63 (31) 16 (20) 0.078
 TIMI coronary flow grade after PCI, n (%)
   0/1 2 (1) 1 (1) 1 (1)  
   2/3 281 (99) 203 (99) 78 (99) 0.481
  TIMI frame count before PCI 29.4 (18.0–44.0) 28.0 (18.0–42.4) 35.9 (25.0–52.5) 0.129 (MW)
  TIMI frame count after PCI 15.3 (10.0–24.7) 16.9 (8.2–22.6) 20.0 (14.6–29.1) <0.001 (MW)
  TIMI blush grade after PCI
   0/1 71 (26) 43 (22) 28 (38) 0.013
   2/3 198 (74) 152 (78) 46 (62)  
  Culprit lesion, residual stenosis, % 12.4 (5.5) 12.3 (5.6) 12.5 (5.4) 0.807 (t)
  CFR 1.6 (1.1–2.1) 1.6 (1.2–2.2) 1.4 (1.0–1.8) <0.001
  IMR 25 (15–44) 18 (13–26) 56 (48–80) <0.001
  Fractional flow reserve 0.90 (0.10) 0.90 (0.09) 0.94 (0.06) 0.006
  Resistive reserve ratio 1.8 (1.4–2.5) 1.9 (1.5–2.6) 1.8 (1.3–2.4) 0.093
Treatment in the catheter laboratory, n (%)
  Aspiration thrombectomy 203 (72) 143 (70) 60 (76) 0.379
  Glycoprotein IIb/IIIa inhibitor 259 (92) 185 (91) 74 (94) 0.485
Medical therapy, n (%)
  ACE-I or ARB 279 (99) 200 (98) 79 (100) 0.579
  β-Blocker 269 (95) 196 (96) 73 (92) 0.225
Initial blood results on admission
  C-reactive protein, mg/L 4 (2–7) 4 (2–7) 4 (2–7) 0.971 (MW)
  Leukocyte cell count, ×109 L 12.4 (3.6) 12.3 (3.4) 12.5 (4.0) 0.743 (t)
  Platelet count, ×106 L 246 (67) 249 (69) 238 (61) 0.193 (t)
  Troponin T, ng/L 1566 (93–4411) 1500 (90–3911) 1967 (106–6465) 0.070 (MW)
ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CFR, coronary flow reserve; IMR, index of microvascular 
resistance; LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; LM, left main coronary artery; MI, myocardial infarction; 
MW, Mann-Whitney; PCI, percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST-segment–elevation myocardial infarction; and TIMI, 
Thrombolysis in Myocardial Infarction. Killip classification of heart failure after acute myocardial infarction: class I, no heart failure; class II, pulmonary rales 
or crepitations, a third heart sound, and elevated jugular venous pressure; class III, acute pulmonary edema; and class IV, cardiogenic shock. 
*Data are reported as mean (SD), median (IQR), or n (%) as appropriate. P values have been obtained from a t test, MW test, or Fisher test. TIMI flow 
grades before and after PCI were grouped as 0/1 versus 2/3 for this analysis. 
†Diabetes mellitus was defined as a history of diet-controlled or treated diabetes mellitus. 
‡Successfully electrically cardioverted ventricular fibrillation at presentation or during emergency PCI procedure. 
§Multivessel coronary artery disease was defined according to the number of stenoses of at least 50% of the reference vessel diameter by visual 
assessment and whether there was LM stem involvement.
table 1. continued
characteristics* all Patients (n=283) iMr≤40 (n=204, 72%) iMr>40 (n=79, 28%) P Value
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with ST-segment resolution (none) and TIMI frame count, 
an IMR>40 was also a multivariable associate with this 
outcome (OR, 4.42; 95% CI, 1.93–10.10; P<0.001). 
The combination of IMR>40 and CFR≤2.0 did not en-
hance the magnitude of the prognostic significance of 
IMR>40 (Table 5).
Fractional Flow reserve and the ratio of cFr to 
Fractional Flow reserve
Fractional flow reserve measured in the culprit coronary 
artery was not associated with myocardial hemorrhage 
status (P=0.262), nor was it associated with LVEDV or 
LVEF at baseline or at follow-up. Fractional flow reserve 
was not associated with health outcomes. Similar results 
were observed for the ratio of CFR to fractional flow re-
serve, which reflects true CFR (Results in the online-only 
Data Supplement).
DiscUssiOn
We have undertaken the largest prospective study of in-
vasive tests of microvascular function, infarct pathology 
revealed by serial CMR, and spontaneous adverse health 
outcomes in patients with acute STEMI.
The main findings are the following: (1) Microvascu-
lar dysfunction at the end of emergency PCI, as clas-
sified by an IMR>40 (without CFR), was more consis-
tently associated with infarct pathology and prognosis 
than symptom-to-reperfusion time or angiographic and 
ECG measures of reperfusion; (2) an IMR>40 was more 
closely associated with myocardial hemorrhage and 
microvascular obstruction than the combination of an 
IMR>40 and CFR≤2.0; (3) an IMR>40 was a multivari-
able associate of the changes in LVEF and LVEDV inde-
pendently of infarct size; and (4) an IMR>40 identifies 
patients who have a 4-fold increase in all-cause death 
Figure 2. cOnsOrt (Consoli-
dated standards of reporting 
trials) flow diagram of the 
cohort study.  
CFR indicates coronary flow reserve; 
CMR, cardiac magnetic resonance; 
IMR, index of microvascular resis-
tance; and STEMI, ST-segment– 
elevation myocardial infarction.
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or heart failure, whereas CFR (or true CFR) alone was 
not associated with this outcome and the combination of 
IMR and CFR had no incremental prognostic value. These 
results refute our hypothesis that the combination of IMR 
with CFR would have superior prognostic value.
implications for Patient Management
Using IMR in patients with acute STEMI, the cardiolo-
gist can focus risk stratification with a simple index that 
has a single cutoff (IMR>40). This test of microvascular 
dysfunction provides incremental prognostic information 
over and above infarct size at an early time point be-
fore infarct size is disclosed by measurement of tropo-
nin or MRI. This result enhances the clinical relevance of 
measuring IMR in patients with acute STEMI. CFR, either 
alone or in combination with IMR, is not needed, and a 
more complicated combined approach with both mea-
sures is not necessary.
Our study adds to the literature on the invasive as-
sessments of the efficacy of myocardial reperfusion 
in patients with acute STEMI.11–13,20–22,47 Fearon et al13 
established that an IMR>40 was independently associ-
ated with all-cause mortality and heart failure; however, 
information on LV function and infarct pathology was 
not described, and the IMR threshold of 40 lacks vali-
dation against infarct pathology and LV outcomes. Our 
table 2. cMr Findings at 2 Days and 6 Months after reperfusion in 283 Patients With steMi categorized 
according to an iMr ≤40 or >40 in the territory of the culprit artery at the end of emergency Pci
characteristics* all Patients (n=283) iMr≤40 (n=145, 51%) iMr>40 (n=65, 23%) P Value
CMR findings 2 d after MI
  LVEF, % 55 (10) 56 (9) 51 (10) <0.001 (t)
  LVEDV, mL     
   Men 160 (32) 158 (32) 165 (34) 0.190 (t)
   Women 124 (25) 126 (23) 120 (29) 0.418 (t)
  LV end-systolic volume, mL     
   Men 75 (26) 72 (24) 82 (30) 0.020 (MW)
   Women 55 (18) 53 (18) 60 (17) 0.130 (MW)
  LV mass, g     
   Men 141 (123 to 160) 141 (123 to 161) 142 (127 to 152) 0.858 (MW)
   Women 95 (85 to 105) 97 (87 to106) 88 (76 to 104) 0.211 (MW)
Edema and infarct characteristics
  Myocardial edema, % LV mass 32 (12) 30 (11) 37 (13) <0.001 (t)
  Infarct size, % LV mass 16 (7 to 27) 14 (4 to 24) 24 (11 to 34) <0.001 (t)
  Myocardial salvage index, % of LV mass 61 (44 to 85) 68 (50 to 87) 49 (39 to 72) <0.001 (t)
  Late microvascular obstruction, n (%) 142 (50) 88 (43) 54 (68) <0.001
  Late microvascular obstruction, % LV mass 0.1 (0.0 to 3.5) 0.0 (0.0 to 2.4) 2.1 (0.0 to 8.4) <0.001 (t)
  Myocardial hemorrhage, n (%) 89 (42) 51 (34) 38 (58) 0.0l
CMR findings 6 mo after MI (n=267)
  LVEF at 6 mo, % 62 (9) 64 (8) 58 (11) <0.001 (t)
  LV end-systolic volume at 6 mo, mL     
   Men 61 (42 to 79) 60 (42, 72) 72 (52, 97) 0.004 (MW)
   Women 41 (33 to 56) 39 (32, 53) 48 (42, 59) 0.060 (MW)
  Change in LVEDV at 6 mo from baseline, mL     
   Men 6 (−8 to 21) 4 (−8 to 16) 13 (−2 to 33) 0.024 (MW)
   Women 1 (−11 to 10) 0 (−11 to 7) 3 (−13 to 19) 0.524 (MW)
CMR indicates cardiac magnetic resonance; IMR, index of microvascular resistance; LV; left ventricular; LVEDV, left ventricular end-diastolic volume; 
LVEF, left ventricular ejection fraction; MI, myocardial infarction; MW, Mann-Whitney; and T1, myocardial longitudinal relaxation time. Area at risk was 
measured with T2 mapping. Data are given as n (%) or mean (SD). P values were obtained from a t test, Mann-Whitney test, or a Fisher test. 
*Data are reported as mean (SD), median (IQR), or n (%) as appropriate. LVEF was missing in 24 subjects at follow-up. LVEDV at follow-up was missing 
in 16 men and 8 women.
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study includes new information with serial CMR. We have 
shown that an IMR>40 is independently associated with 
infarct pathology, changes in LV function and volume, 
and all-cause-death or heart failure. On the other hand, 
the prognostic significance of CFR was less than that of 
IMR, and CFR was not additive to IMR. CFR has greater 
hemodynamic dependence; it is subject to variations in 
resting flow, is not specific for the microvasculature, and 
has a narrower range of values.14,48
CFR reflects the functional (vasodilator) capacity of 
the coronary artery circulation,48 whereas IMR reflects 
microvascular resistance. Park et al16 undertook a prog-
nostic study of IMR and CFR in 89 patients with acute 
STEMI. They found that the combination of an increased 
IMR and reduced CFR was associated with changes in 
LV wall motion score index at 3 months as revealed by 
echocardiography and major adverse cardiac and cere-
brovascular events. The results of this study lend sup-
port to the theory that the combination of IMR and CFR 
might have additive prognostic value compared with ei-
ther index alone. Compared with the study by Park et 
al,16 our study included a population that was 3 times 
larger, advanced cardiac imaging with MRI, independent 
analysis of spontaneous adverse cardiac events, and a 
composite outcome that did not include revasculariza-
tion. Furthermore, another small study (n=40)18 in pa-
tients with acute STEMI showed that the combination of 
high IMR and low CFR enhanced the predictive accuracy 
of detecting microvascular obstruction compared with 
either index alone. The results from our study refute 
those of Park et al16 and Ahn et al18 and indicate that an 
IMR>40 is sufficient for prognostication.
In the acute clinical setting, failed myocardial reperfu-
sion, as reflected by microvascular obstruction and myo-
cardial hemorrhage, occurs in about half of all patients 
with STEMI and commonly passes undetected acutely. 
Microvascular obstruction is potentially reversible,4 but 
without successful myocardial reperfusion, severe vas-
cular damage progresses to irreversible myocardial 
hemorrhage in 40% of all patients.3–5 When CMR is per-
formed days later, it is too late for early intervention to 
prevent or treat severe microvascular damage, and CMR 
has limited availability in routine practice.
An IMR>40 was consistently associated with in-
farct pathology, changes in LV function and volumes 
independently of infarct size, and all-cause death or 
table 3. Multivariable associations Between 
clinical characteristics, iMr>40 at the end of 
emergency Pci, and the Occurrence of Myocardial 
hemorrhage 2 Days later (n=200) in Patients With 
acute steMi
Binary logistic regression Or (95% ci) P Value
IMR>40 2.86 (1.52–5.39) 0.001
Male sex 2.75 (1.32–5.72) 0.007
Smoker 2.08 (1.11–3.90) 0.023
Hypertension 1.98 (1.04–3.74) 0.037
Harrell C statistic 0.684  
CI indicates confidence interval; IMR, index of microvascular resistance; 
and OR, odds ratio. Manual backward selection was used with a P value 
threshold of 0.10 for inclusion. Previous percutaneous coronary intervention 
was excluded because numeric instability. The multivariable association 
for IMR>40 and coronary flow reserve ≤2.0 with myocardial hemorrhage 
was 2.51 (95% CI, 1.28–4.91; P=0.007; Harrell C statistic=0.671).
table 4. Multivariable associations Between an 
iMr>40 and changes in lVeDV at 6 Months From 
Baseline (n=264)
linear regression coefficient (95% ci) P Value
Baseline LVEDV −0.23 (−0.35 to −0.12) <0.001
Infarct size 1.03 (0.75 to 1.30) <0.001
BMI 1.16 (0.41 to 1.90) 0.003
Hypercholesterolemia −10.55 (−18.13 to −2.97) 0.007
Male sex 11.27 (3.05 to 19.49) 0.007
IMR>40 7.85 (0.41 to 15.29) 0.039
Diabetes mellitus −10.15 (−20.24 to −0.06) 0.049
TIMI blush grade 2/3  
after PCI 
−6.06 (−13.21 to 1.08) 0.096
Hypertension 5.13 (−1.99 to 12.25) 0.157
TIMI frame count after PCI −0.16 (−0.42 to 0.11) 0.241
Heart rate −0.10 (−0.30 to 0.09) 0.298
Previous PCI −8.63 (−25.80 to 8.55) 0.323
Age −0.14 (−0.47 to 0.19) 0.410
Smoker 3.00 (−4.22 to 10.23) 0.413
Culprit lesion, percentage 
residual stenosis
0.09 (−0.51 to 0.70) 0.758
Symptom-to-reperfusion 
time per 10 min
0.01 (−0.13 to 0.15) 0.894
Previous MI −0.48 (−16.18 to 15.21) 0.952
Previous angina −0.23 (−10.56 to 10.09) 0.965
SBP per 10 mm Hg −0.01 (−1.35 to 1.32) 0.984
Bayesian information 
criterion
2137  
BMI indicates body mass index; CI, confidence interval; IMR, index of 
microvascular resistance; LVEDV, left ventricular end-diastolic volume; 
MI, myocardial infarction; PCI, percutaneous coronary intervention; SBP, 
systolic blood pressure; and TIMI, Thrombolysis in Myocardial Infarction. A 
combination of IMR>40 and CFR≤2.0 was not a multivariable associate of 
the change in LVEDV at 6 months from baseline when infarct size (percent 
LV mass) was included in the model (P=0.059). In a model that included 
peak troponin (μg/L), the multivariable association for IMR>40 and 
CFR≤2.0 with the change in LVEDV at 6 months from baseline was 10.68 
(95% CI, 2.23–19.12; P=0.014; Bayesian information criterion=2080). 
According to the Bayesian information criteria, there was no improvement 
in the model that included IMR>40 and CFR≤2.0.
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heart failure compared with other standard measures 
of reperfusion injury, including TIMI frame count, TIMI 
myocardial perfusion grade, and ST-segment reso-
lution.24,49 In our population, a minority of patients 
(14%) had no evidence of ST-segment resolution 60 
minutes after reperfusion, yet microvascular obstruc-
tion and myocardial hemorrhage occurred in 50% and 
42% of patients, respectively. TIMI myocardial perfu-
sion grade was not associated with clinical outcomes 
(Table 5) and is difficult to reliably measure in clinical 
practice. Reliable measurement of failed reperfusion 
at the end of the PCI procedure is therefore a difficult 
clinical conundrum, not least because coronary reper-
fusion is successfully achieved in the majority of all 
patients.
Our results have important clinical implications. Failed 
myocardial reperfusion in patients with acute STEMI is 
common, is associated with adverse outcome, and of-
ten goes unnoticed, largely because current assessment 
methods lack sensitivity and routine CMR, usually per-
formed days after the acute event, is often not practical 
or cost-efficient. Immediate detection of failed myocardi-
al reperfusion becomes feasible with IMR, is safe,50 and 
allows direct stratification of the highest-risk patients at 
the time of emergency reperfusion, when early therapeu-
tic interventions may yield the greatest clinical benefit. 
Conversely, the possibility remains that an IMR>40 may 
represent an unmodifiable marker of elevated risk.
implications for therapy and clinical trials
Further research is warranted to investigate preventive 
or therapeutic interventions in patients stratified by IMR 
to assess whether IMR-guided strategies might improve 
prognosis compared with standard care.
Our results provide evidence both for and against IMR 
as identifying modifiable risk (hence a target for treat-
ment) as opposed to being only an unmodifiable marker 
of elevated risk (and hence not a target for treatment). 
The modifiable associations include myocardial salvage 
index, microvascular obstruction, and myocardial hem-
orrhage (all of which are linked to the pathophysiology 
of LV remodeling), and nonmodifiable associations (eg, 
body mass index, Killip class at presentation, area at risk 
[myocardial edema] which are essentially markers for in-
creased myocardial mass at risk). Although IMR might of-
fer an opportunity to guide therapy, it may mostly reflect 
a larger area at risk and thus be unmodifiable. Only an 
outcomes-based, randomized, controlled trial will decide 
the issue.
There is some evidence that IMR is responsive to the 
effects of treatments known to have favorable cardiovas-
cular effects, including vasodilators51 and anti-ischemic52 
therapies. During PCI, compared with a direct stenting 
approach without initial balloon angioplasty, a predilata-
tion step to disrupt and modify the plaque before stent-
ing is associated with a higher IMR at the end of the PCI 
procedure.53 In the setting of acute STEMI, a randomized 
trial of initial antiplatelet therapy in 76 patients undergo-
ing primary PCI disclosed that, compared with an oral 
loading dose of 600 mg clopidogrel, an oral loading dose 
of 180 mg ticagrelor was associated with a lower IMR at 
the end of the procedure (22.2±18.0 versus 34.4±18.8 
U; P=0.005).54 In other randomized, controlled trials in 
acute MI, IMR is being used to assess the comparative 
efficacy of antiplatelet therapies55 (NCT0273334), vaso-
dilator therapy,56 and low-dose intracoronary thromboly-
sis (T-TIME [A Trial of Low-Dose Adjunctive alteplase Dur-
ing Primary PCI]; NCT02257294).
table 5. relationships Between iMr and cFr and 
all-cause Death or First hospitalization for heart 
Failure During or after the index hospitalization 
Obtained With logistic regression
associations Or (95% ci) P Value
Univariable associations
  IMR>40 4.36 (2.10–9.06) <0.001
  IMR (for a 5-unit change) 1.08 (1.05–1.12) <0.001
  IMR>median 2.16 (1.01–4.61) 0.047
  CFR≤2.0, IMR>40 4.37 (2.13–8.97) <0.001
  CFR≤median, IMR>median 2.96 (1.24–7.08) 0.015
  CFR (for a 0.2-unit change) 0.92 (0.82–1.02) 0.124
  CFR≤median 1.74 (0.81–3.72) 0.153
  CFR≤2.0 1.17 (0.50–2.72) 0.721
Multivariable associations
  Model A (n=283)
   IMR>40 4.70 (2.10–10.53) <0.001
   Cigarette smoker 2.49 (1.01–6.14) 0.048
   Hypertension 2.84 (1.26–6.42) 0.012
   IMR>40, CFR ≤2.0 5.01 (2.22–11.33) <0.001
   Cigarette smoker 2.69 (1.08–6.69) 0.033
   Hypertension 2.84 (1.26–6.42) 0.12
  Model B (n=282)
   IMR >40 4.42 (1.93–10.10) <0.001
   No ST-segment resolution 2.49 (1.01–6.15) 0.049
   TIMI frame count after PCI 1.00 (0.97–1.03) 0.823
   IMR>40, CFR≤2.0 4.46 (1.96–10.15) <0.001
   No ST-segment resolution 2.58 (1.04–6.38) 0.041
   TIMI frame count after PCI 1.00 (0.97–1.03) 0.866
CFR indicates coronary flow reserve; CI, confidence interval; IMR, index 
of microvascular resistance; OR, odds ratio; PCI, percutaneous coronary 
intervention; and TIMI, Thrombolysis in Myocardial Infarction. The median 
duration of follow-up was 845 days (postdischarge censor duration range, 
598–1098 days). Thirty patients (10.4%) died or experienced an index 
heart failure event.
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sample size calculation and clinical trials
In addition to the study design, estimated treatment effect, 
and power, the key factor that will influence the sample 
size in a clinical trial in which IMR is used as measure of 
treatment effect is the variance in IMR for the population 
studied. T-TIME is a randomized, placebo-controlled trial 
of 2 reduced doses of alteplase (10 and 20 mg) adminis-
tered directly into the culprit coronary artery after reperfu-
sion but before stent implantation. In that trial, we have 
estimated that if the median IMR is 33.9 (SD, 25.2) and 
the IMR values are 27.2 and 20.5 in the 10- and 20-mg 
dose groups, respectively, then 80 subjects per group 
would be needed. This calculation is based on an average 
difference in IMR between treatment and placebo of 10, 
assuming that there is a linear trend with dose. If the aver-
age difference in IMR between treatment and placebo is 
13, then 48 subjects per group would be needed.
limitations
We performed a single-center, natural-history study. The 
median IMR in our population was 25, which is compa-
rable to previous IMR values in some12,23 but not all11,13 
cohorts of patients with STEMI. IMR is associated with 
infarct size11 and potentially the duration of ischemia. 
The ischemic time in our population was relatively short 
(Table 1), which potentially explains IMR distribution in 
our population. There was a comparatively lower propor-
tion of patients with an anterior STEMI in our cohort (37% 
of patients) compared with, for example, 49% of cases 
in the study by McGeoch et al11 (median IMR, 35) and 
55% of cases in the study by Fearon et al13 (median IMR, 
31). These studies involved fewer patients, and enroll-
ment may have been more selective. IMR measurement 
involves a diagnostic guidewire and use of intravenous 
adenosine and may prolong the procedure by ≈5 min-
utes. In 2013, the US Food and Drug Administration is-
sued a safety announcement on the risk of MI and death 
in patients receiving Adenoscan (adenosine) for stress 
testing. However, a subsequent prospective, multicenter 
study has shown that intravenous adenosine when ad-
ministered briefly for invasive physiology testing is safe 
and well tolerated in patients with acute or recent MI.50 
IMR was measured routinely in our catheter laboratories, 
with measurements obtained by all of the cardiologists 
(n=13) without complication and in the setting of routine 
emergency care.
Most of the adverse events occurred initially during 
the index hospitalization. The limited number of adverse 
events constrained the statistical power of the multivari-
able models of adverse health outcomes. The study pop-
ulation included 21 patients initially treated with throm-
bolysis, and 14 of these patients had rescue PCI. The 
main results of our study were unchanged when these 
patients were removed (data not shown). The limited 
number of adverse events constrained the number of 
variables and related statistical power in the prognostic 
models. Our analysis does not permit inference on cau-
sality, and further studies are warranted.
conclusions
Compared with the angiographic and ECG measures of 
reperfusion, the combination of IMR>40 and CFR≤2.0, 
and CFR alone, an IMR>40 is consistently and strongly 
associated with microvascular pathology, changes in LV 
function and volumes, and all-cause death and heart fail-
ure in the longer term. Our results validate previous in-
vestigations and support further research into IMR-based 
therapeutic strategies.
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1Supplementary Methods 
Comparative prognostic utility of indices of microvascular function alone or in 
combination in patients with an acute ST-segment elevation myocardial infarction. 
ClinicalTrials.gov identifier: NCT02072850. 
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Setting and study populations 
STEMI patients 
Screening, enrolment, and data collection were prospectively performed by cardiologists in 
the cardiac catheterization laboratories of the Golden Jubilee National Hospital, Glasgow, 
United Kingdom. This hospital is a regional referral centre for primary and rescue 
percutaneous coronary intervention (PCI). The hospital provides clinical services for a 
population of 2.2 million. A screening log was recorded, including patients who did not 
participate in the cohort study. Patients were invited to undergo cardiac magnetic resonance 
imaging (CMR) 2 days and 6 months after hospital admission (1)(2). 
Coronary angiogram acquisition 
Coronary angiograms were acquired during usual care with cardiac catheter laboratory X-ray 
(Innova) and IT equipment (Centricity) made by GE Healthcare.  
Percutaneous coronary intervention 
Consecutive admissions with acute STEMI referred for emergency percutaneous coronary 
intervention (PCI) were screened for the inclusion and exclusion criteria. During ambulance 
transfer to the hospital, the patients received 300 mg of aspirin, 600 mg of clopidogrel and 
5000 IU of unfractionated heparin (3, 4). The initial primary PCI procedure was performed 
using radial artery access. A conventional approach to primary PCI was adopted in line with 
usual care in our hospital (3, 4). Conventional bare metal and drug eluting stents were used in 
line with guideline recommendations and clinical judgement. The standard transcatheter 
approach for reperfusion involves minimal intervention with aspiration thrombectomy only or 
minimal balloon angioplasty (e.g. a compliant balloon sized according to the reference vessel 
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diameter and inflated at 4-6 atmospheres 1-2 times). During PCI, glycoprotein IIbIIIa 
inhibitor therapy was initiated with high dose tirofiban (25 g/kg/bolus) followed by an 
intravenous infusion of 0.15 g/kg/min for 12 hours, according to clinical judgement and 
indications for bail-out therapy (3, 4). No reflow was treated according to contemporary 
standards of care with intra-coronary nitrate (i.e. 200 g) and adenosine (i.e. 30 – 60 g) (3, 
4), as clinically appropriate. In patients with multivessel coronary disease, multivessel PCI 
was not recommended, in line with clinical guidelines (3, 4). The subsequent management of 
these patients was symptom-guided. 
Measurement of IMR and CFR at the end of PCI 
We adopted a thermodilution technique rather than Doppler, in order to implement a method 
that is potentially transferable to routine clinical practice. The Doppler measurements are 
more time-consuming, require considerable experience, may be less reproducible (14), and 
the guidewire is typically more expensive. The Doppler method less transferrable to every-
day practice than the thermodilution method. 
A coronary pressure- and temperature-sensitive guidewire (St Jude Medical, Uppsala, 
Sweden) was used to measure coronary flow reserve (CFR) and the index of microvascular 
resistance (IMR) in the culprit coronary artery at the end of primary or rescue PCI. The 
guidewire was calibrated outside the body, equalized with aortic pressure at the ostium of the 
guide catheter and then advanced to the distal third of the culprit artery. Coronary flow 
reserve is defined as the mean transit time at rest divided by the mean transit time during 
hyperemia.  
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IMR is defined as the distal coronary pressure multiplied by the mean transit time of a 3 ml 
bolus of saline at room temperature during maximal coronary hyperemia, measured 
simultaneously (mmHg x s, or units) (5-7).  
Hyperemia was induced by 140 /kg/min of intravenous adenosine preceded by a 2 ml 
intracoronary bolus of 200 µg of nitrate. The mean aortic and distal coronary pressures were 
recorded during maximal hyperemia. We have previously assessed the repeatability of IMR 
using duplicate measurements 5 minutes apart in a subset of 12 consecutive patients (7). 
A priori, based on the prior literature, we pre-specified and examined an IMR>40 and also 
the following classifications: 1) IMR≤40 and CFR>2.0, 2) IMR>40 and CFR>2.0), 3) 
IMR≤40 and CFR≤2.0, 4) IMR>40 and CFR≤2.0.  
Angiographic analysis 
Coronary artery anatomy 
The coronary anatomy and disease characteristics of the study participants were described 
based on the clinical reports of the attending cardiologist. Coronary dominance were assigned 
as left, right or balanced according to the origin of the posterior descending coronary artery.  
Coronary artery disease severity 
Quantitative coronary analysis (QCA) of the culprit vessel was performed by two trained 
observers (J.C., V.Y.T.M) using standard methods (Centricity, GE Healthcare, Pollards 
Wood, UK).  All coronary angiograms were analysed on a single image analysis software 
platform using de-identified images. Automatic edge detection algorithms were used to 
determine the vessel contours by assessing brightness along scan lines perpendicular to the 
vessel center.  Image analysis was performed by two experienced observers supervised by an 
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expert physician, all of whom were blinded to the other study data. End-diastolic frames were 
used to assess disease severity using angulations reveal the stenosis at its most severe degree 
with minimal foreshortening and branch overlap.  The coronary artery segments in the culprit 
artery included all those with a reference diameter 1.5 mm.  
Definitions 
TIMI flow grade 
Coronary blood flow can be described based on the visual assessment of coronary blood flow 
revealed by contrast injection into the coronary arteries (3, 4, 8).  
TIMI Coronary Flow Grade  
0 No flow 
1 Minimal flow past obstruction 
2 Slow (but complete) filling and slow clearance 
3 Normal flow and clearance 
Myocardial perfusion 
Angiographic evidence of myocardial perfusion will be evaluated using the TIMI myocardial 
perfusion grade (TMP) at the end of the PCI procedure (9).  
Grade  
0 No myocardial blush 
1 Minimal blush and very slow clearing (e.g. present at 
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beginning of next cine) 
2 Good blush with slow clearing of myocardial contrast 
(present at end of cine but gone at beginning of next) 
3 Good blush and normal clearing (ie. gone by end of cine) 
 
Assessment by corrected Thrombolysis In Myocardial Infarction Frame Count 
Corrected TIMI frame count (cTFC) was calculated as the number of frames for dye to reach 
a standardised distal landmark in each angiographic territory. The first frame taken for the 
measurement was the frame in which dye touched both borders of the coronary artery in 
question and moved forward with at least 70% of the vessel lumen opacified. The 
standardised distal landmarks were taken as the first branch of the postero-lateral artery for 
the right coronary artery, the most distal branch of the obtuse marginal for the circumflex, 
and the distal bifurcation of the left anterior descending (LAD) coronary artery. The number 
of frames from the first frame to the last frame when the dye entered the standardised distal 
landmark was counted. A standard image acquisition speed of 30 frames per second was 
used. The correction factor used to account for the increased length of the LAD compared to 
the right and circumflex arteries was 1.7 thereby giving a “corrected TIMI frame count”. 
CMR acquisition and analyses 
We used CMR to provide reference data on LV function, pathology and surrogate outcomes, 
independent of the invasive tests.  
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CMR acquisition 
CMR was performed on a Siemens MAGNETOM Avanto (Erlangen, Germany) 1.5-Tesla 
scanner with a 12-element phased array cardiac surface coil. T2 maps were acquired in 
contiguous short axis slices covering the whole ventricle, using an investigational prototype 
T2-prepared (T2P) TrueFisp sequence (10, 11). Typical imaging parameters were: bandwidth 
~947 Hz/pixel; flip angle 70°; T2 preparations: 0 ms, 24 ms, and 55 ms respectively; matrix 
160 x 105 pixels; spatial resolution 2.6 x 2.1 x 8.0 mm; slice thickness 8 mm. 
T2*-maps were obtained using an investigational prototype T2* map sequence acquired in 3 
short-axis slices (basal, mid and apical). Typical imaging parameters were: bandwidth ~814 
(x8) Hz/pixel; flip angle 18°; matrix 256x115; spatial resolution 2.6 x 1.6 x 10 mm; slice 
thickness 8 mm. 
In order to assess early microvascular obstruction, early gadolinium enhancement imaging 
was acquired 1, 3, 5 and 7 minutes post-contrast injection using a TrueFISP readout and fixed 
inversion time (TI) of 440 ms. Late gadolinium enhancement images covering the entire LV 
were acquired 10-15 minutes after intravenous injection of 0.15 mmol/kg of gadoterate 
meglumine (Gd2+-DOTA, Dotarem, Guebert S.A.) using segmented phase-sensitive inversion 
recovery (PSIR) turbo fast low-angle shot (12). Microvascular obstruction was defined as a 
dark zone on early delayed enhancement imaging 1, 3, 5 and 7 minutes post-contrast injection 
and within an area of late gadolinium enhancement. Typical imaging parameters were: matrix 
= 192 x 256, flip angle = 25, TE = 3.36 ms, bandwidth = 130 Hz/pixel, echo spacing = 
8.7ms and trigger pulse = 2. The voxel size was 1.8 x 1.3 x 8 mm3. Inversion times were 
individually adjusted to optimize nulling of apparently normal myocardium (typical values, 
200 to 300 ms). 
  9 
 
MR image analyses 
The images were analysed on a Siemens work-station by observers with at least 3 years CMR 
experience (N.A., D.C., I.M). All of the images were reviewed by experienced CMR 
cardiologists (C.B., N.T.). LV dimensions, volumes and ejection fraction were quantified 
using computer assisted planimetry (syngo MR®, Siemens Healthcare, Erlangen, Germany). 
All scan acquisitions were spatially co-registered.  
T2 and T2* – standardized measurements in myocardial regions of interest  
LV contours were delineated with computer assisted planimetry on the raw T2* image and 
the last corresponding T2 raw image, with echo time of 55 ms (13). Contours were then 
copied onto the colour-encoded spatially co-registered maps and corrected when necessary by 
consulting the SSFP cine images. Apical segments were not included because of partial 
volume effects. Particular care was taken to delineate regions of interest with adequate 
margins of separation from tissue interfaces prone to partial volume averaging such as 
between myocardium and blood. Each T2/ T2* map image was visually assessed for the 
presence of artefacts relating to susceptibility effects or cardio-respiratory motion. Each map 
was evaluated against the original images. When artefacts occurred, the affected segments 
were not included in the analysis. 
T2/ T2* values were segmented spatially and regions of interest were defined as (1) remote 
myocardium, (2) injured myocardium and (3) infarct core. The regions-of-interest were 
planimetered to include the entire area of interest with distinct margins of separation from 
tissue interfaces to exclude partial volume averaging. The remote myocardial region-of-
interest was defined as myocardium 180º from the affected zone with no visible evidence of 
infarction, edema or wall motion abnormalities (assessed by inspecting corresponding 
contrast enhanced T1-weighted, T2-weighted and cine images, respectively). The infarct zone 
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region-of-interest was defined as myocardium with pixel values (T2) >2 SD from remote 
myocardium on T2-weighted CMR (10, 11). The infarct core was defined as an area in the 
center of the infarct territory having a mean T2/ T2* value of at least 2 standard deviations 
(SDs) below the T2/ T2* value of the periphery of the area-at-risk.  
In healthy volunteers, the mid-ventricular T2/T2* map was segmented into 6 equal segments, 
using the anterior right ventricular-LV insertion point as the reference point (2). T2/T2* was 
measured in each of these segments, and regions-of-interest were planimetered distinct and 
separate from blood-pool and tissue interfaces. These segmental values were also averaged to 
provide one value per subject. Results are presented as average values for segments and 
slices.   
Infarct definition and size 
The presence of acute infarction was established based on abnormalities in cine wall motion, 
rest first-pass myocardial perfusion, and delayed-enhancement imaging. In addition, 
supporting changes on the ECG and coronary angiogram were also required. Acute infarction 
was considered present only if late gadolinium enhancement was confirmed on both the axial 
and long axis acquisitions. The myocardial mass of late gadolinium (grams) was quantified 
using computer assisted planimetry and the territory of infarction was delineated using a 
signal intensity threshold of >5 standard deviations above a remote reference region and 
expressed as a percentage of total LV mass (14). Infarct regions with evidence of 
microvascular obstruction were included within the infarct area and the area of microvascular 
obstruction was assessed separately and also expressed as a percentage of total LV mass. The 
measurements of infarct size were performed by I.M. and N.A. 
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Microvascular obstruction 
Microvascular obstruction was defined as a dark zone on EGE imaging 1, 3, 5 and 7 minutes 
post-contrast injection that remained present within an area of late gadolinium enhancement 
at 15 minutes. Identification of microvascular obstruction was performed independently by 
I.M. and N.A. 
Myocardial hemorrhage 
Myocardial hemorrhage was scored visually. On the T2* maps, a region of reduced signal 
intensity within the infarcted area, with a T2* value of <20 ms (15-18), was considered to 
confirm the presence of myocardial hemorrhage. 
Myocardial edema 
The extent of myocardial edema was defined as LV myocardium with pixel values (T1/T2) 
>2 standard deviations from remote myocardium (10, 11, 19-22).  
Myocardial salvage 
Myocardial salvage was calculated by subtraction of percent infarct size from percent area-at-
risk (7, 19, 22). The myocardial salvage index was calculated by dividing the myocardial 
salvage area by the initial area-at-risk. 
Adverse remodeling 
Adverse remodeling was defined as an increase in LV end-diastolic volume ≥ 20% at 6 
months from baseline (23). 
Reference ranges 
Reference ranges used in the laboratory were 105 – 215 g for LV mass in men, 70 – 170 g for 
LV mass in women, 77 – 195 ml for LV end-diastolic volume in men, 52 – 141 ml for LV 
end-diastolic volume in women, 19 – 72 ml for LV end-systolic volume in men and 13 – 51 
ml for LV end-systolic volume in women.  
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Electrocardiogram 
A 12 lead electrocardiogram (ECG) was obtained before coronary reperfusion and 60 minutes 
afterwards with Mac-Lab technology (GE Healthcare) in the catheter laboratory and a 
MAC 5500 HD recorder (GE Healthcare) in the Coronary Care Unit. The ECGs were 
acquired by trained cardiology staff. The ECGs were de-identified and transferred to the local 
ECG management system. The ECGs were then analysed by the University of Glasgow ECG 
Core Laboratory which is certified to ISO 9001: 2008 standards as a UKAS Accredited 
Organization.  
The extent of ST-segment resolution on the ECG assessed 60 minutes after reperfusion 
compared to the baseline ECG before reperfusion (3) was expressed as complete (70%), 
incomplete (30% to < 70%) or none (30%). ECG evidence of reperfusion injury was taken 
as persistence of ST segment elevation resolution post-procedure, and specifically 30% ST-
segment resolution post-PCI. 
Biochemical and hematologic measurements 
Blood samples were obtained immediately after reperfusion in the cardiac catheterization 
laboratory, and subsequently between 0600 - 0700 hrs each day during the initial in-patient 
stay in the Coronary Care Unit.  
Biochemical assessment of infarct size 
Troponin T was measured (Elecsys Troponin T, Roche) as a biochemical measure of infarct 
size. The high sensitive assay reaches a level of detection of 5 pg/ml and achieves less than 
10% variation at 14 pg/ml corresponding to the 99th percentile of a reference population. The 
peak troponin T value for each patient was recorded in the study database.  
  13 
 
Biochemical assessment of inflammation 
C-reactive protein (CRP) was measured in an NHS hospital biochemistry laboratory using a 
particle enhanced immunoturbimetric assay method (Cobras C501, Roche) and the 
manufacturers calibrators and quality control material, as a biochemical measure of 
inflammation. The high sensitive assay CRP measuring range is 0.1-250 mg/L. The expected 
CRP values in a healthy adult are < 5 mg/L, and the reference range in our hospital is 0 - 10 
mg/L.  
Hematological measurement of inflammation 
Leucocyte count and leucocyte sub-populations were measured as a hematologic measure of 
inflammation using sheath flow technology incorporating semi-conductor laser beam, 
forward and side scattered light  (Sysmex XT200i and XT1800i for white blood cell and 
differential white blood cell counts, respectively). The linearity ranges for white blood cells 
was 0.00-440.0 x10(9) /L. The following are the normal ranges for full blood count 
parameters: 
 MALE FEMALE 
WBC x  10^9/L 4.0 - 11.0 4.0 - 11.0 
RBC x 10^12/L 4.50 - 6.50 3.80 - 5.80 
Hgb g/L 130 – 180 115 - 165 
HCT L/L 0.400 - 0.540 0.370 - 0.470 
MCV fL 78 – 99 78 - 99 
MCH Pg 27.0 - 32.0 27.0 - 32.0 
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MCHC g/L 310 – 360 310 - 360 
PLATELETS x 10^9/L 150 – 400 150 - 400 
NEUTROPHILS x 10^9/L 2.5 - 7.5 2.5 - 7.5 
LYMPHOCYTES x 10^9/L 1.5 - 4.0 1.5 - 4.0 
MONOCYTES x 10^9/L 0.2 - 0.8 0.2 - 0.8 
EOSINOPHILS  x 10^9/L 0.0 - 0.4 0.0 - 0.4 
BASOPHILS x 10^9/L 0.01 - 0.10 0.01 - 0.10 
A blood sample was routinely obtained in the cardiac catheter laboratory, immediately 
following revascularization and then again at 0700 on the first and second days after 
admission to hospital.  
Pre-specified health outcomes 
We pre-specified adverse health outcomes that are pathophysiologically linked with STEMI 
(43, 44). The primary composite outcome was (1) all-cause death or first heart failure event 
following the initial hospitalization (Supplementary Methods).  
Research staff screened for events from enrolment by checking the medical records 
and by contacting patients and their primary and secondary care physicians, as appropriate 
with no loss to follow-up (Figure 2). Each serious adverse event (SAE) was reviewed by a 
cardiologist who was independent of the research team and blinded to all of the clinical and 
CMR data. The SAEs were defined according to standard guidelines (43, 44) (Supplementary 
Methods) and categorized as having occurred either during the index admission or post-
discharge. All study participants were followed-up for a minimum of 18 months after 
discharge. The median duration of follow-up was of 845 days (post-discharge censor duration 
(range) 598 - 1098 days).  
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Statistics 
Sample size calculation for the whole cohort  
With an estimated hemorrhage incidence of 33% at 48 h post-STEMI, 100 subjects would 
have evidence of myocardial hemorrhage and 200 subjects would not. The study would have 
90% power at a 5% level of significance using a two sided two sample t-test to detect a 
between-group difference in a baseline variable of interest e.g. index of microvascular 
resistance equivalent to three eighths of a common standard deviation. We also estimated that 
at least 30 major adverse cardiac events (MACE) would occur based on a conservative 
estimate of the event rate (10-12%) at 18 months. The sample size calculation was performed 
using nQuery version 7.0. 
Statistical analysis 
Categorical variables are expressed as the number and percentage of patients. Most 
continuous variables followed a normal distribution and are therefore presented as means 
together with standard deviation. Those variables that did not follow a normal distribution are 
presented as medians with interquartile range. Differences in continuous variables between 
groups were assessed by the Student’s t-test or ANOVA for continuous data with normal 
distribution, otherwise the nonparametric Mann-Whitney test or Kruskal-Wallis H test. 
Differences in categorical variables between groups were assessed using a Fisher’s test. 
Two raters assessed the angiograms of 30 subjects randomly selected from the whole 
cohort. Inter-rater reliability for angiographic parameters was assessed using weighted 
Cohen’s kappa and the intra-class correlation coefficient (ICC) with random effects 
models  (Supplementary Results). 
Univariable and multivariable associations are assessed using binary logistic 
regression or linear regression where appropriate.  Binary logistic models are compared using 
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Harrel’s C-statistic.  Linear regression models are compared using the Bayesian Information 
Criterion (BIC). The likelihood ratio test was used to compare the binary logistic and linear 
regression models with IMR, or an IMR>40 and CFR≤2.0. A p-value <0.05 favors including 
the variable in the model. 
Logistic regression (odds ratio, 95% confidence interval) was used to identify 
potential clinical predictors of all-cause death/heart failure events, including patient 
characteristics, CMR findings, and IMR and CFR.   
All p-values are 2-sided and a p-value > 0.05 indicates the absence of a statistically 
significant effect.  Statistical analyses were performed using R version 2.15.1 or SAS v 9.3, 
or higher versions of these programs. 
Trial Management 
The study was conducted in line with Guidelines for Good Clinical Practice (GCP) in Clinical 
Trials. http://www.mrc.ac.uk/documents/pdf/good-clinical-practice-in-clinical-trials/  
Trial management included a Trial Management Group, and an independent Clinical Trials 
Unit. Day to day study activity was coordinated by the Trial Management Group who was 
responsible to the Sponsor which was responsible for overall governance and that the trial 
was conducted according to GCP standards.  
Clinical events were assessed and validated by an independent cardiologist (A.M.) who had 
access to relevant source clinical data. This cardiologist followed an agreed charter and he 
was blinded to all of the other clinical data.  
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Supplementary Results 
Comparative prognostic utility of indices of microvascular function alone or in 
combination in patients with an acute ST-segment elevation myocardial 
infarction. 
ClinicalTrials.gov identifier: NCT02072850.  
2 
Reproducibility 
Inter-rate reliability  
Two raters assessed the angiograms of 25 randomly selected participants. The 
weighted Cohen’s kappa for initial TIMI flow was 0.84 (0.92, 0.99) and the Cohen’s 
kappa for final TIMI flow was 0.62 (0.87, 1.0). The weighted Cohen’s kappa for 
TIMI myocardial blush grade was 0.10 (0.35, 0.61).The intra-class correlation 
coefficient for TIMI frame count was 0.75 (0.54, 0.87). 
CFR/FFR ratio, a measure of true CFR 
In a multivariable model for predictors of the changes in LV ejection fraction at 
baseline, the ratio of CFR/FFR was associated with LVEF, independent of other 
parameters (coefficient (95% CI) 0.96 (0.04, 1.88); p=0.041), however, when IMR 
was included in this model, the relationship for CFR/FFR was no longer statistically 
significant (0.77 (-0.17, 1.71); p=1.08). 
CFR/FFR was not a multivariable predictor of LVEDV when included alone (p=0.33) 
or in combination with IMR (p=0.661) whereas IMR was a multivariable associate of 
LV EDV (0.71 (0.02, 1.40); p=0.043). 
3 
Table 1. Clinical and angiographic characteristics of 283 STEMI patients with culprit artery microvascular function at the end of emergency PCI 
categorized as follows 1) IMR ≤40 and CFR >2.0, 2) IMR >40 and CFR >2.0), 3) IMR ≤40 and CFR ≤2.0, 4) IMR >40 and CFR ≤2.0. 
Characteristics*  All patients CFR>2.0, 
IMR≤40 
CFR>2.0,   
IMR>40 
CFR≤2.0, 
IMR≤40 
CFR≤2.0, 
IMR>40 
P-value 
  n = 283 n = 59 (21%) n = 14 (5%) n = 145 (51%) n = 65 (23%)  
Age, years  60 (12) 57 (12) 56 (10) 60 (11) 63 (12) 0.002 
Male sex, n (%)  206 (73) 46 (78) 8 (57) 101 (70) 51 (79) 0.230 
BMI, (kg/m2)  29 (5) 30 (5) 27 (6) 29 (5) 28 (4) 0.024 
Medical history        
Hypertension, n (%)  91 (32) 16 (27) 5 (36) 44 (30) 26 (40) 0.407 
Current smoking, n (%)  175 (62) 37 (63) 11 (79) 93 (64) 34 (52) 0.225 
Hypercholesterolemia, n (%)  78 (28) 18 (31) 6 (43) 37 (26) 17 (26) 0.509 
Diabetes mellitus‡, n (%)  30 (11) 3 (5) 1 (7) 18 (12) 8 (12) 0.438 
Previous angina, n (%)  32 (11) 4 (7) 2 (14) 18 (12) 8 (12) 0.634 
Previous myocardial infarction, n (%)  20 (7) 4 (7) 0 (0) 11 (8) 5 (8) 0.944 
4 
Previous PCI, n (%)  14 (5) 2 (3) 0 (0) 7 (5) 5 (8) 0.681 
Presenting characteristics        
Heart rate, bpm  78 (17) 77 (19) 78 (15) 78 (16) 78 (17) 0.853 
Systolic blood pressure, mmHg  136 (24) 138 (27) 137 (23) 134 (24) 136 (24) 0.524 
Diastolic blood pressure, mmHg  79 (14) 80 (12) 82 (10) 78 (15) 80 (14) 0.580 
Time from symptom onset to reperfusion, 
min 
 174 (120, 316) 163 (112, 281) 240 (149, 454) 183 (120, 304) 175 (129, 336) 0.384 
Ventricular fibrillation†, n (%)  19 (7) 3 (5) 2 (14) 8 (6) 6 (9) 0.360 
Heart failure, Killip class at presentation, n 
(%) I 
201 (71%) 57 (80) 10 (71) 111 (76) 33 (51)  
 II 62 (22%) 10 (17) 4 (29) 30 (21) 18 (28) <0.001 
 III/IV 20 (7) 2 (3) 0 (0) 4 (3) 14 (21)  
ECG        
ST segment elevation resolution post PCI, n 
(%)  
      
Complete, 70 %  128 (45) 32 (54) 6 (43) 69 (48) 21 (32)  
Incomplete, 30% to < 70%  114 (40) 20 (34) 5 (36) 59 (41) 30 (46) 0.148 
5 
None, 30%  40 (14) 7 (12) 3 (21) 16 (11) 14 (22)  
Reperfusion strategy, n (%)        
Primary PCI  262 (93) 55 (93) 14 (100) 134 (92) 59 (91)  
Rescue PCI (failed thrombolysis)  14 (5) 3 (5) 0 (0) 7 (5) 6 (6) 0.995 
Successful thrombolysis  7 (2) 1 (2) 0 (0) 4 (3) 2 (3)  
Coronary angiography        
Number of diseased arteries¥, n (%) 1 158 (56) 34 (58) 7 (50) 78 (54) 39 (60)  
 2 83 (29) 16 (27) 6 (43) 45 (31) 16 (25) 0.979 
 3 37 (13) 8 (14) 1 (7) 19 (13) 9 (14)  
 LM 5 (2) 1 (2) 0 (0) 3 (2) 1 (2)  
Culprit artery, n (%)  LAD 107 (38) 23 (39) 5 (36) 49 (34) 30 (46)  
 LCX 51 (18) 10 (17) 2 (14) 29 (20) 10 (15) 0.791 
 RCA 125 (44) 26 (44) 7 (50) 67 (46) 25 (39)  
TIMI coronary flow grade pre-PCI, n (%)  0/1 204 (72) 37 (62) 10 (71) 104 (72) 53 (82)  
 2 51 (18) 11 (19) 3 (21) 28 (19) 9 (14) 0.190 
 3 28 (10) 11 (19) 1 (7) 13 (9) 3 (5)  
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TIMI coronary flow grade post-PCI, n (%) 0/1 2 (1) 0 (0) 0 (0) 1 (1) 1 (2)  
 2 13 (5) 1 (2) 2 (14) 3 (2) 7 (11) 0.017 
 3 268 (95) 58 (98) 12 (86) 141 (97) 57 (88)  
TIMI frame count pre-PCI  29.4 (18.0, 44.0) 27.1 (16.0, 42.4) 28.0 (18.9, 34.0) 28.0 (19.5, 38.5) 41.0 (25.7, 55.0) 0.182 
TIMI frame count post-PCI  15.3 (10.0, 24.7) 16.0 (10.0, 24.0) 22.6 (17.0, 26.0) 12.9 (8.0, 22.0) 20.0 (14.0, 30.0) <0.001 
TIMI blush grade post-PCI 0/1 71 (26.4%) 20 (35.1%) 3 (23.1%) 23 (16.7%) 25 (41.0%) 0.001 
 2/3 198 (73.6%) 37 (64.9%) 10 (76.9%) 115 (83.3%) 36 (59.0%)  
Culprit lesion, percentage residual stenosis  12.4 (5.5) 12.12 (5.67) 14.05 (4.12) 12.42 (5.62) 12.18 (5.57) 0.948 
Aspiration thrombectomy, n (%)   203 (72) 43 (73) 13 (93) 100 (69) 47 (72) 0.307 
Coronary flow reserve  1.8 (0.9) 3.1 (1.0) 2.7 (0.7) 1.4 (0.3) 1.3 (0.4) <0.001 
Index of microvascular resistance  24 (15, 44) 19 (13, 25) 49 (43, 53) 18 (13, 27) 63 (49, 93) <0.001 
Fractional flow reserve  0.90 (0.10) 0.92 (0.08) 0.96 (0.07) 0.90 (0.09) 0.93 (0.06) 0.027 
Resistive reserve ratio  1.8 (1.4, 2.5) 3.3 (2.8, 4.0) 2.8 (2.6, 3.5) 1.7 (1.3, 1.9) 1.5 (1.2, 2.0) <0.001 
Treatment in the catheter laboratory        
Thrombus aspiration  203 (71.7%) 43 (72.9%) 13 (92.9%) 100 (69.0%) 47 (72.3%) 0.307 
Glycoprotein IIbIIIa inhibitor  259 (91.5%) 52 (88.1%) 14 (100.0%) 133 (91.7%) 60 (92.3%) 0.631 
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Medical therapy        
ACE-I or ARB  279 (99) 58 (98) 14 (100) 143 (98) 65 (100) 0.723 
Beta-blocker  269 (95) 55 (93) 12 (86) 141 (97) 61 (94) 0.132 
Initial blood results on admission        
C-reactive protein, (mg/L)  8 (21) 6 (6) 11 (24) 7 (11) 13 (38) 0.774 
Leucocyte cell count (x109L)  12.4 (3.6) 12.2 (3.7) 12.9 (4.2) 12.4 (3.3) 12.4 (4.0) 0.731 
Neutrophil count (x109L)  9.6 (3.3) 9.2 (3.4) 10.3 (4.3) 9.7 (3.1) 9.8 (3.6) 0.278 
Monocytes (x109L)  0.9 (0.4) 0.9 (0.3) 0.9 (0.4) 0.8 (0.3) 0.9 (0.5) 0.602 
Platelet count (x106L)  246 (67) 239 (66) 245 (58) 253 (70) 237 (62) 0.883 
Troponin T (ng/L)  1566 (93, 4411) 1272 (106, 2675) 1727 (1727, 1727) 1731 (85, 4302) 2717 (111, 7419) 0.023 
Footnote: ACE-I or ARB = angiotensin converting enzyme inhibitor or angiotensin receptor blocker; LAD = Left anterior descending coronary 
artery; LCX = Left circumflex coronary artery; LM = left main coronary artery; RCA = right coronary artery; TIMI = Thrombolysis in 
Myocardial Infarction grade, PCI = percutaneous coronary intervention. Killip classification of heart failure after acute myocardial infarction: 
class I - no heart failure, class II - pulmonary rales or crepitations, a third heart sound, and elevated jugular venous pressure, class III - acute 
pulmonary edema, class IV - cardiogenic shock. * Data are reported as mean (SD), median (IQR), or N (%) as appropriate. P-values have been 
obtained from a one-way ANOVA, Kruskal-Wallis test or Fisher test. TIMI flow grades pre- and post-PCI were grouped 0/1 vs. 2/3 for this 
analysis. ‡ Diabetes mellitus was defined as a history of diet-controlled or treated diabetes. † Successfully electrically cardioverted ventricular 
fibrillation at presentation or during emergency PCI procedure. ¥ Multivessel coronary artery disease was defined according to the number of 
stenoses of at least 50% of the reference vessel diameter, by visual assessment and whether or not there was left main stem involvement.  
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Table 2. Cardiac magnetic resonance imaging findings at 2 days and 6 months post-reperfusion in 283 STEMI patients with culprit artery 
microvascular function categorized as follows 1) IMR ≤40 and CFR >2.0, 2) IMR >40 and CFR >2.0), 3) IMR ≤40 and CFR ≤2.0, 4) IMR >40 
and CFR ≤2.0. 
Characteristics* All patients CFR>2.0, 
IMR≤40 
CFR>2.0, 
IMR>40 
CFR≤2.0, 
IMR≤40 
CFR≤2.0, 
IMR>40 
P-value 
 n = 283 n = 59 (21%) n = 14 (5%) n = 145 (51%) n = 65 (23%)  
CMR findings 2 days post-MI  
      
LV ejection fraction, %  55 (10) 56 (9) 54 (9) 57 (9) 51 (10) 0.027 
LV end-diastolic volume, ml       
Men 160 (32) 160 (30) 167 (29) 158 (33) 165 (35) 0.628 
Women 124 (25) 124 (25) 130 (38) 126 (23) 116 (24) 0.461 
LV end-systolic volume, ml       
Men 74 (54, 92) 70 (54, 89) 74 (69, 78) 73 (50, 86) 81 (59, 104) 0.106 
Women 53 (41, 67) 46 (43, 59) 73 (54, 78) 51 (40, 68) 61 (51, 65) 0.338 
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LV mass, g       
Men 141 (123, 160) 140 (120, 157) 144 (130, 152) 141 (123, 163) 142 (127, 153) 0.994 
Women 95 (85, 105) 101 (85, 116) 105 (97, 123) 97 (87, 104) 85 (76, 90) 0.088 
Edema and infarct characteristics 
      
Myocardial edema, % LV mass 32 (12) 28 (11) 33 (6) 31 (11) 38 (14) <0.001 
Infarct size, % LV mass 16 (7, 27) 11 (4, 21) 14 (7, 24) 11 (3, 22) 24 (12, 33) <0.001 
Myocardial salvage index, % of LV mass 61 (44, 85) 71 (56, 90) 60 (47, 91) 67 (47, 86) 46 (39, 67) <0.001 
Late microvascular obstruction, n (%) 142 (50) 17 (29) 9 (64) 71 (49) 45 (69) <0.001 
Late microvascular obstruction, % LV mass 0.1 (0.0, 3.5) 0.0 (0.0, 0.5) 1.7 (0.0, 4.5) 0.0 (0.0, 2.7) 2.1 (0.0, 9.4) <0.001 
Myocardial hemorrhage, n (%) 89 (42) 8 (21) 10 (48) 22 (31) 48 (60) <0.001 
CMR findings 6 months post-MI (n=267) 
      
LV ejection fraction at 6 months, % 62 (9) 65 (7) 61 (10) 64 (9) 57 (11) <0.001 
LV end-diastolic volume at 6 months, ml       
10 
Men 165 (136, 192) 161 (135, 189) 192 (172, 209) 165 (132, 187) 170 (141, 212) 0.113 
Women 121 (109, 136) 118 (102, 130) 124 (99, 146) 122 (111, 135) 130 (110, 135) 0.877 
Change in LV end-diastolic volume at 6 months 
from baseline, ml 
      
Men 6 (-8, 21) 4 (-8, 14) 13 (4, 19) 5 (-9, 18) 13 (-6, 33) 0.145 
Women 1 (-11, 10) -1 (-5, 11) -13 (-16, 2) 0 (-11, 7) 9 (-3, 19) 0.242 
Footnote: Abbreviations: LV = left ventricle, T1 = myocardial longitudinal relaxation time. Area-at-risk was measured with T2-mapping. Data 
are given as n (%) or mean (SD). P-values were obtained from one-way ANOVA, Kruskal-Wallis test, or a Fisher test. * Data are reported as 
mean (SD), median (IQR), or n (%) as appropriate. LV ejection fraction was missing in 24 subjects at follow-up. LV end-diastolic volume at 
follow-up was missing in 16 men and 8 women. 
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Table 3. Multivariable associations between clinical characteristics, an increased IMR>40 at 
the end of emergency PCI, and myocardial obstruction revealed by contrast-enhanced MRI 
two days later (n=262) in patients with acute STEMI.* 
Binary logistic regression  Odds ratio (95% CI) p value 
Index of microvascular resistance >40 2.82 (1.62, 4.93) <0.001 
Male gender 1.78 (1.03, 3.09) 0.039 
Hypertension 1.31 (0.77, 2.23) 0.311 
Cigarette smoker 1.23 (0.74, 2.04) 0.429 
Harrel’s C-statistic 0.634  
* Manual backwards selection using a p-value threshold of 0.10 for inclusion. Previous PCI 
was excluded due to numerical instability. Likelihood ratio test, p=0.005, favouring inclusion 
of IMR>40 in the model. The multivariable association for IMR>40, CFR≤2.0 in this model 
was 2.75 (1.51, 5.02); p=0.001; Harrel’s C-statistic = 0.626). 
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Table 4. Multivariable associations between an IMR>40 and the changes in left ventricular 
ejection fraction at 6 months from baseline. 
Linear regression  Coefficient (95% CI) p value 
Baseline LV ejection fraction, % -0.64 (-0.74, -0.53) <0.001 
Infarct size, % LV mass -0.31 (-0.39, -0.23) <0.001 
Previous MI -5.44 (-9.40, -1.48) 0.007 
TIMI blush grade post-PCI (2  or 3 vs. 1) 2.10 (0.30, 3.91) 0.022 
Index of microvascular resistance >40 -2.12 (-4.02, -0.23) 0.028 
No-resolution of ST-elevation 2.31 (-0.03, 4.64) 0.053 
Previous PCI 4.09 (-0.23, 8.42) 0.064 
   
BMI, kg/m2 -0.14 (-0.32, 0.04) 0.116 
Hypercholesterolemia 1.05 (-0.86, 2.97) 0.279 
Male sex -1.03 (-2.91, 0.85) 0.283 
TIMI frame count post PCI 0.03 (-0.04, 0.09) 0.412 
Culprit lesion, percentage residual stenosis -0.05 (-0.21, 0.10) 0.476 
   
Diabetes mellitus 0.90 (-1.66, 3.47) 0.487 
Smoker -0.54 (-2.36, 1.29) 0.560 
Symptom to reperfusion time per 10 minutes 0.01 (-0.03, 0.05) 0.572 
Age (years) 0.02 (-0.07, 0.10) 0.682 
Previous angina 0.48 (-2.13, 3.10) 0.716 
Hypertension -0.18 (-2.01, 1.64) 0.844 
SBP per 10 mmHg 0.02 (-0.31, 0.36) 0.892 
   
Heart rate (bpm) 0.00 (-0.05, 0.05) 0.894 
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Bayesian Information Criterion 1520.33  
The Bayesian Information Criterion (BIC) reflects the goodness of fit of a multivariable 
model, where a smaller criterion indicates a preferable model. Likelihood ratio test, p=0.005, 
favors inclusion of IMR>40 in the model.  
An IMR>40 was a multivariable associate of the change in left ventricular ejection fraction at 
6 months from baseline in a different model that included infarct size as reflected by troponin 
concentration (co-efficient (95% CI) -2.73 (-4.76, -0.69); p=0.001;  BIC 1489). 
In a model that included infarct size (% LV mass) as revealed by MRI, the multivariable 
association for IMR>40, CFR≤2.0 with the change in left ventricular ejection fraction at 6 
months from baseline was -1.91 (-3.94, 0.12); p=0.066 (BIC 1521.91).  In a model that 
included peak troponin (g/L), the multivariable association for IMR>40, CFR≤2.0 with the 
change in left ventricular ejection fraction at 6 months from baseline was -2.38 (-4.58, -0.19); 
p=0.034; BIC 1491). According to the BICs, there was no improvement in the model 
including for IMR>40, CFR≤2.0.  
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Table 5. 
 
Breakdown of all cause death or heart failure events (n=30) 
Breakdown of all cause death or heart failure events during index hospital admission 
Death n = 1 
Heart failure (requiring IV furosemide) n = 19 
 
Breakdown of all cause death or heart failure events post-discharge  
Death n = 7 
Heart failure (requiring IV furosemide) n = 3 
 
 
